Phathom Pharmaceuticals Inc (PHAT) is a biopharmaceutical company that is focused on the development of therapies for gastrointestinal diseases. The company's lead product candidate, PH-105, is a novel, pH-sensitive inhibitor of gastrin, which is being developed for the treatment of gastroesophageal reflux disease (GERD).
GERD is a common, chronic condition in which acid from the stomach flows back into the esophagus, causing symptoms such as heartburn and acid regurgitation. PH-105 has the potential to be a first-in-class treatment for GERD, as it is designed to target the root cause of the disease by inhibiting the production of gastrin, a hormone that stimulates the production of stomach acid.
In addition to PH-105, Phathom is also developing a second product candidate, PH-200, which is a novel, investigational drug for the treatment of eosinophilic esophagitis (EoE). EoE is a chronic, allergic inflammatory disease of the esophagus that is characterized by high levels of eosinophils, a type of white blood cell.
Phathom has an experienced management team with a track record of success in developing and commercializing innovative therapies for gastrointestinal diseases. The company's focus on unmet needs in this area, along with its promising product candidates, make it an interesting company to watch in the biopharmaceutical space.
|
